Dexdor

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
14-07-2022
Toote omadused Toote omadused (SPC)
14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
01-10-2018

Toimeaine:

Dexmedetomidine hydrochloride

Saadav alates:

Orion Corporation

ATC kood:

N05CM18

INN (Rahvusvaheline Nimetus):

dexmedetomidine

Terapeutiline rühm:

Psycholeptics

Terapeutiline ala:

Conscious Sedation

Näidustused:

For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Toote kokkuvõte:

Revision: 16

Volitamisolek:

Authorised

Loa andmise kuupäev:

2011-09-15

Infovoldik

                                24
B. PACKAGE LEAFLET
25
PACKAGE LEAFLET: INFORMATION FOR THE USER
DEXDOR 100 MICROGRAMS/ML CONCENTRATE FOR SOLUTION FOR INFUSION
dexmedetomidine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Dexdor is and what it is used for
2.
What you need to know before you are given Dexdor
3.
How to use Dexdor
4.
Possible side effects
5.
How to store Dexdor
6.
Contents of the pack and other information
1.
WHAT DEXDOR IS AND WHAT IT IS USED FOR
Dexdor contains an active substance called dexmedetomidine which
belongs to a medicine group
called sedatives. It is used to provide sedation (a state of calm,
drowsiness or sleep) for adult patients
in hospital intensive care settings or awake sedation during different
diagnostic or surgical procedures.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DEXDOR
YOU MUST NOT BE GIVEN DEXDOR
-
if you are allergic to dexmedetomidine or any of the other ingredients
of this medicine (listed in
section 6)
-
if you have some disorders of heart rhythm (heart block grade 2 or 3)
-
if you have very low blood pressure which does not respond to
treatment
-
if you have recently had a stroke or other serious condition affecting
blood supply to the brain.
WARNINGS AND PRECAUTIONS
Before you have this medicine, tell your doctor or nurse if any of the
following apply as Dexdor
should be used cautiously:
-
if you have an abnormally slow heart rate (either due to illness or
high levels of physical fitness)
as it may increase the risk for cardiac arrest
-
if you have low blood pressure
-
if you have low blood volume, for example after bleeding
-
if you have certain heart disorders
-
if you are elderly
-
if you have a neurological disorder (for instance head o
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dexdor 100 micrograms/ml concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml of concentrate contains dexmedetomidine hydrochloride
equivalent to 100 micrograms
dexmedetomidine.
Each 2 ml ampoule contains 200 micrograms of dexmedetomidine.
Each 2 ml vial contains 200 micrograms of dexmedetomidine.
Each 4 ml vial contains 400 micrograms of dexmedetomidine.
Each 10 ml vial contains 1 000 micrograms of dexmedetomidine.
The concentration of the final solution after dilution should be
either 4 micrograms/ml or
8 micrograms/ml.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear, colourless solution, pH 4.5–7.0
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For sedation of adult ICU (Intensive Care Unit) patients requiring a
sedation level not deeper than
arousal in response to verbal stimulation (corresponding to Richmond
Agitation-Sedation Scale
(RASS) 0 to -3).
For sedation of non-intubated adult patients prior to and/or during
diagnostic or surgical procedures
requiring sedation, i.e. procedural/awake sedation.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
FOR SEDATION OF ADULT ICU (INTENSIVE CARE UNIT) PATIENTS REQUIRING A
SEDATION LEVEL NOT DEEPER
THAN AROUSAL IN RESPONSE TO VERBAL STIMULATION (CORRESPONDING TO
RICHMOND AGITATION-SEDATION
SCALE (RASS) 0 TO -3).
For hospital use only. Dexdor should be administered by healthcare
professionals skilled in the
management of patients requiring intensive care.
Posology
Patients already intubated and sedated may switch to dexmedetomidine
with an initial infusion rate of
0.7 micrograms/kg/h which may then be adjusted stepwise within the
dose range 0.2 to
1.4 micrograms/kg/h in order to achieve the desired level of sedation,
depending on the patient’s
response. A lower starting infusion rate should be considered for
frail patients. Dexmedetomid
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 14-07-2022
Toote omadused Toote omadused bulgaaria 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 01-10-2018
Infovoldik Infovoldik hispaania 14-07-2022
Toote omadused Toote omadused hispaania 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 01-10-2018
Infovoldik Infovoldik tšehhi 14-07-2022
Toote omadused Toote omadused tšehhi 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 01-10-2018
Infovoldik Infovoldik taani 14-07-2022
Toote omadused Toote omadused taani 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande taani 01-10-2018
Infovoldik Infovoldik saksa 14-07-2022
Toote omadused Toote omadused saksa 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande saksa 01-10-2018
Infovoldik Infovoldik eesti 14-07-2022
Toote omadused Toote omadused eesti 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande eesti 01-10-2018
Infovoldik Infovoldik kreeka 14-07-2022
Toote omadused Toote omadused kreeka 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 01-10-2018
Infovoldik Infovoldik prantsuse 14-07-2022
Toote omadused Toote omadused prantsuse 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 01-10-2018
Infovoldik Infovoldik itaalia 14-07-2022
Toote omadused Toote omadused itaalia 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 01-10-2018
Infovoldik Infovoldik läti 14-07-2022
Toote omadused Toote omadused läti 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande läti 01-10-2018
Infovoldik Infovoldik leedu 14-07-2022
Toote omadused Toote omadused leedu 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande leedu 01-10-2018
Infovoldik Infovoldik ungari 14-07-2022
Toote omadused Toote omadused ungari 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande ungari 01-10-2018
Infovoldik Infovoldik malta 14-07-2022
Toote omadused Toote omadused malta 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande malta 01-10-2018
Infovoldik Infovoldik hollandi 14-07-2022
Toote omadused Toote omadused hollandi 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 01-10-2018
Infovoldik Infovoldik poola 14-07-2022
Toote omadused Toote omadused poola 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande poola 01-10-2018
Infovoldik Infovoldik portugali 14-07-2022
Toote omadused Toote omadused portugali 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande portugali 01-10-2018
Infovoldik Infovoldik rumeenia 14-07-2022
Toote omadused Toote omadused rumeenia 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 01-10-2018
Infovoldik Infovoldik slovaki 14-07-2022
Toote omadused Toote omadused slovaki 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 01-10-2018
Infovoldik Infovoldik sloveeni 14-07-2022
Toote omadused Toote omadused sloveeni 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 01-10-2018
Infovoldik Infovoldik soome 14-07-2022
Toote omadused Toote omadused soome 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande soome 01-10-2018
Infovoldik Infovoldik rootsi 14-07-2022
Toote omadused Toote omadused rootsi 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 01-10-2018
Infovoldik Infovoldik norra 14-07-2022
Toote omadused Toote omadused norra 14-07-2022
Infovoldik Infovoldik islandi 14-07-2022
Toote omadused Toote omadused islandi 14-07-2022
Infovoldik Infovoldik horvaadi 14-07-2022
Toote omadused Toote omadused horvaadi 14-07-2022
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 01-10-2018

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu